Companies / BOC Sciences / Mirikizumab
BOC Sciences

Mirikizumab | BOC Sciences

Mirikizumab is a p19-directed antibody against interleukin-23. Mirikizumab showed efficacy in a phase 2 trial involving patients with ulcerative colitis.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.